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FE and RE methods. CONCLUSIONS: Cisplatin significantly increased the RR of 
nephrotoxicity compared to non-cisplatin regimens when SCr was used to 
screen patients for inclusion in clinical trials, but only showed a trend toward a 
smaller increase in RR when GFR was used.  
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OBJECTIVES: To examine the clinical characteristics and treatment patterns of 
colorectal cancer patients in the U.S. veteran population. METHODS: A study 
sample from the Veterans Health Administration (VHA) Medical SAS datasets 
from October 1, 2005 through May 31, 2012 was analyzed. All patients diagnosed 
with colorectal cancer throughout the study period were identified using 
International Classification of Disease 9thRevision Clinical Modification (ICD-9-
CM) diagnosis codes 153.xx and 154.xx. Descriptive statistical analyses were 
performed using SAS v9.3 software. RESULTS: There were 62,200 diagnosed 
colorectal cancer patients in the VHA population during the study period. Major 
comorbidities for these colorectal cancer patients were hypertension (n=18,309, 
29.44%) and diabetes (n=10,891, 17.51%). Other minor comorbidities included 
hyperlipidemia and benign neoplasm of the colon. Common treatments 
prescribed for colorectal cancer patients were simvastatin and omeprazole. 
Outpatient services were utilized by 99.71% of colorectal cancer patients, 
followed by pharmacy (91.94%) and inpatient visits (31.15%). Costs for outpatient 
($10,637, standard deviation [SD]=$17,125), pharmacy ($2,704, SD=$9,773), and 
inpatient services ($16,032, SD=$53,078) contributed to follow-up health care 
expenditures. Out of all colorectal cancer patients, 7,596 (12.21%) had Occult 
Blood (Fecal) Test results, with an average test result of 96.37. CONCLUSIONS: 
Colorectal cancer treatment is complicated by the presence of both major and 
minor comorbidities. Further analysis in the context of complicated comorbid 
conditions is required to improve the overall burden of illness of colorectal 
cancer patients.  
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OBJECTIVES: To examine the economic burden and clinical characteristics of 
lung cancer in the U.S. veteran population. METHODS: A retrospective database 
analysis was performed using the Veterans Health Administration (VHA) Medical 
SAS Datasets from October 1, 2005 to May 31, 2012. Patients with lung cancer 
were identified using International Classification of Disease 9th Revision Clinical 
Modification (ICD-9-CM) diagnosis code 162.xx. Descriptive statistics were 
calculated as means ± standard deviation (SD) and percentages to measure 
comorbidities, laboratory tests, costs and utilization distribution in the sample. 
Comorbidities and laboratory tests were measured for the 1-year baseline period 
before the disease identification date. Health care costs and utilization were 
measured for the 1-year follow-up period after the identification date. RESULTS: 
The total number of lung cancer patients identified in the study period was 
73,150. The most common comorbidities of these patients were hypertension 
(n=21,377, 29.22%), chronic airway obstruction (n=14,305, 19.56%), abnormal 
findings on radiological and other examination of lung field (n=12,437, 17.00%), 
and diabetes (n=11,569, 15.82%). Omeprazole and simvastatin were the top two 
most commonly prescribed treatments for lung cancer patients. Both 
medications were prescribed for more than 20% of all lung cancer patients. A 
total of 49,706 (67.95%) of the lung cancer patients had total white blood cell 
(WBC) count test results, averaging a result of 11.68. The percentage of patients 
with follow-up inpatient visits was 46.47%, which translated into $21,420 of 
inpatient costs per patient. 99.11% of patients had follow-up outpatient visits, 
which translated into $12,986 total outpatient costs per patient ($12,110 for office 
visit, $411 for emergency room visit costs). CONCLUSIONS: This study found that 
omeprazole and simvastatin were the most frequently prescribed drugs after a 
lung cancer diagnosis. However, more research is required to better understand 
adverse events and side effects.  
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OBJECTIVES: To evaluate the efficacy and safety of the monoclonal antibody 
rituximab (RIT) for the treatment of patients with indolent or aggressive non-
Hodgkin lymphoma B cells (B-NHL). METHODS: We searched The Cochrane 
Library, Centre for Reviews and Dissemination, Tripdatabase, Medline and 
LILACS databases aiming to find systematic reviews (SR) and randomized clinical 
trials (RCT) comparing RIT regimens versus RIT free regimens for induction or 
maintenance treatment of indolent and aggressive B-NHL. Health Technology 
Assessments (HTA) were searched on agencies websites. Quality of the evidence 
and strength of recommendation were evaluated using the GRADE system. 
RESULTS: We selected thirteen SR, eight RCT and six HTA publications. Half of 
the SR and the majority of RCT were classified as poor quality. The strength of 
recommendation was considered weak in favor of RIT in all studies. Combined 
overall survival meta-analysis showed a relative risk of 1.09 (1.06; 1.12) benefiting 
RIT treated patients. Overall survival for aggressive NHL non-RIT treated patients 
was 0.53 (0.37; 0.77). The death hazard ratio for indolent B-NHL RIT treated 
patients were 0.65 (0.54; 0.78) and 0.76 (0.62; 0.92). Individual studies also showed 
benefits of increased overall survival for RIT treated patients. The studies 
showed a higher incidence of serious adverse events with RIT regimens, such as 
granulocytopenia and leucopenia, which did not appear to lead to increased 
infections or mortality rates. HTA publications recommended the use of RIT 
regimens as first-line therapy for aggressive and indolent B-NHL or as second-
line therapy and maintenance for indolent B-NHL. CONCLUSIONS: Evidences 
support the use of RIT in combination with chemotherapy as first-line and 
second-line treatment for aggressive B-NHL. For patients with follicular indolent 
B-NHL, RIT is recommended in combination with chemotherapy for patients 
previously treated or not, and for the maintenance of patients who responded to 
treatment after second-line chemotherapy.  
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OBJECTIVES: Anti-angiogenic therapy has become an integral component of 
treatment for metastatic colorectal cancer patients. During the last 10 years, 
several studies were conducted to test the safety and efficacy of anti-angiogenic 
therapies in mCRC patients. This study reviewed the results of randomized 
controlled trials published in peer-reviewed journals. METHODS: We searched 
the MEDLINE, and abstracts from ECCO, ESMO and ASCO until January 2013. 
Studies were selected for randomized controlled trials on targeted anti-
angiogenic drugs in mCRC. Primary endpoints reviewed were progression-free 
(PFS) and overall survival (OS). Response rates, toxicity and secondary 
resectability were secondary endpoints. Aggregated data were further analyzed 
to understand comparative safety and efficacy. RESULTS: Until January 2013, 
eligible mCRC randomized clinical trials for this review were available for 
bevacizumab (6 trials including 4523 patients), Cediranib ( 2 trials including 2282 
patients), vatalanib (2 trials including 2033 patients) and aflibercept (1 trial 
including 1226 patients). Overall, anti-angiogenesis therapy for mCRC shows 
significant OS and PFS benefit versus comparators. The median OS and PFS 
benefit for regimens containing Bevacizumab were 3 and 3.15 months, versus 
background chemotherapy. The median OS and PFS benefit for vatalanib 
containing regimens were statistically insignificant versus background 
chemotherapy. CONCLUSIONS: Anti-angiogenesis therapy with Bevacizumab for 
mCRC shows significant OS and PFS benefit versus comparators.  
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OBJECTIVES: Breast cancer is the most common cancer in women as well as the 
principle cause of death from cancer among women worldwide. Approximately 
20%–30% of women with breast cancer over-express the human epidermal 
growth factor receptor 2 (HER2), which promotes the growth of cancer 
cells.Trastuzumab is a recombinant humanized monoclonal antibody that 
targets HER2. It has been shown to be effective as monotherapy and, as adjuvant 
therapy, has been shown to improve results of chemotherapy in patients with 
HER2-positive metastatic breast cancer. The objective of this study was to 
conduct a meta-analysis of the available evidence on the benefit of receiving 
adjuvant trastuzumab in HER2-positive breast cancer patients who are 
concomitantly receiving chemotherapy. METHODS: We performed a literature 
search in MEDLINE® (1996 to 2012) to find peer-reviewed publications and 
academic conference proceedings relevant to the objective. A meta-analysis of 
randomized controlled trials comparing chemotherapy patients with or without 
adjuvant trastuzumab treatment was conducted. The primary outcome was 
disease-free survival (DFS), while a secondary outcome was mortality. Both the 
random-effects model and the fixed-effect model were used to combine and 
analyze data. RESULTS: Six eligible clinical trials were identified, and 14,299 
patients with HER2-positive breast cancer were included. Results indicated 
superior outcomes in the adjuvant trastuzumab group relative to the group 
without trastuzumab. For DFS, the trastuzumab group had an odds ratio (OR) of 
0.62 (95% CI: 0.48-0.80).For mortality, it had an OR of 0.77 (95% CI: 0.64-0.93). 
CONCLUSIONS: According to the meta-analysis, adjuvant trastuzumab therapy 
both improves DFS and reduces mortality relative to patients treated with 
chemotherapy only. Other issues surrounding trastuzumab include optimum 
length of therapy, the high cost of therapy, and the high risk of cardiovascular 
side effects, which may themselves lead to death.  
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OBJECTIVES: Evaluate the efficacy, safety and cost estimates of sorafenib 
compared to other therapeutic options for the treatment of metastatic renal cell 
carcinoma (mRCC). METHODS: Systematic reviews (SR) of clinical trials 
comparing sorafenib with other therapeutic options were searched in The 
Cochrane Library, Medline, Lilacs, Centre for Reviews and Dissemination and 
Tripdatabase. We also selected health technology assessments (HTA) reports. 
Monthly treatment costs of the inhibitors of vascular endothelial growth factor 
